Home
Affimed

Affimed Market Share Analysis for November 2025

Site will be available soon. Thank you for your patience!

Health > Biotechnology and Pharmaceuticals

Domainaffimed.com

Year Founded2000

Employees51 - 200

Annual Revenue$25M - $50M

Affimed

Affimed (including company regionals)

affimed.com

See more website traffic and engagement information

Affimed Revenue up to November 2025 is 25M - 50M

revenue generated by Affimed top domains

Affimed top domains revenue over 3 years

Revenue for Affimed top domains

affimed.com25M - 50M

See more with Sales Intelligence

Total visits to Affimed's top domains

Understand Affimed market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

affimed.com1.2K

See more with Sales Intelligence

Avg. visit duration in Affimed's top domains

Analyze Affimed engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

affimed.com00:01:22

See more with Sales Intelligence

Avg. pageviews on Affimed's top domains

See how Affimed keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

affimed.com2.30

See more with Sales Intelligence

Affimed top competitors by domain

Top similar sites in November 2025, ranked by their affinity

adamaspharma.comCompany NameAdamas PharmaceuticalsEmployees51 - 200HQUnited States, California, EmeryvilleAnnual revenue$50M - $75MTotal visits--Health > Biotechnology and Pharmaceuticals

Top technologies used by Affimed

These are the website technologies, by industry, used by Affimed top domains

Payment & Currencies (3)

Euro

Widget (3)

reCAPTCHA

Conversion & Analytics (2)

Google Analytics

Mobile (2)

Meta Viewport

More Technologies

4

See all

News & Signals from Affimed

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAffimed NV attends event 2025 Annual Meeting.MANNHEIM, Germany, April 29, 2025 (GLOBE NEWSWIRE) - Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today presented findings on an exposure-outcome analysis of its innate cell engager (ICE(R) AFM24, in patients with advanced or metastatic non-small cell lung cancer (NSCLC) in a poster session at the 2025 Annual Meeting of the American Association for Cancer Research (AACR).

NewsAffimed NV attends event 2025 American Society for Clinical Oncology (ASCO) Annual Meeting.Affimed N.V. (Nasdaq: AFMD) has announced the acceptance of three abstracts for presentation at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago.

NewsAffimed NV hired Shawn M. Leland as Chief Executive Officer on Sep 3rd '24.MANNHEIM, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) - Affimed N.V. (Nasdaq: AFMD) ("Affimed" or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that Shawn M. Leland, PharmD, RPh has been appointed as Chief Executive Officer (CEO).